

AD\_\_\_\_\_

Award Number: W81XWH-10-1-0169

TITLE: Novel Inhibitors of Protein-Protein Interaction for Prostate Cancer Therapy

PRINCIPAL INVESTIGATOR: George Wilding, M.D.

CONTRACTING ORGANIZATION: University of Wisconsin  
Madison, WI 53715-1218

REPORT DATE: April 2013

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

| REPORT DOCUMENTATION PAGE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |             |                          |                            | Form Approved<br>OMB No. 0704-0188               |                                           |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|--------------------------|----------------------------|--------------------------------------------------|-------------------------------------------|
| Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.                                                                                                                                                                          |             |                          |                            |                                                  |                                           |
| 1. REPORT DATE<br>April 2013                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |             | 2. REPORT TYPE<br>Annual |                            | 3. DATES COVERED<br>1 April 2012 – 31 March 2013 |                                           |
| 4. TITLE AND SUBTITLE<br><br>Novel Inhibitors of Protein-Protein Interaction for Prostate Cancer Therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |             |                          |                            | 5a. CONTRACT NUMBER                              |                                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |             |                          |                            | 5b. GRANT NUMBER<br>W81XWH-10-1-0169             |                                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |             |                          |                            | 5c. PROGRAM ELEMENT NUMBER                       |                                           |
| 6. AUTHOR(S)<br><br>George Wilding, M.D.<br><br>E-Mail: gxw@medicine.wisc.edu                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |             |                          |                            | 5d. PROJECT NUMBER                               |                                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |             |                          |                            | 5e. TASK NUMBER                                  |                                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |             |                          |                            | 5f. WORK UNIT NUMBER                             |                                           |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)<br><br>University of Wisconsin<br>Madison, WI 53715-1218                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |             |                          |                            | 8. PERFORMING ORGANIZATION REPORT NUMBER         |                                           |
| 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)<br>U.S. Army Medical Research and Materiel Command<br>Fort Detrick, Maryland 21702-5012                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |             |                          |                            | 10. SPONSOR/MONITOR'S ACRONYM(S)                 |                                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |             |                          |                            | 11. SPONSOR/MONITOR'S REPORT NUMBER(S)           |                                           |
| 12. DISTRIBUTION / AVAILABILITY STATEMENT<br>Approved for Public Release; Distribution Unlimited                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |             |                          |                            |                                                  |                                           |
| 13. SUPPLEMENTARY NOTES                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |             |                          |                            |                                                  |                                           |
| 14. ABSTRACT<br><br>The goal of this research is to firmly establish the mechanism of androgen receptor (AR)-JunD heterodimer induction of the SSAT gene leading to oxidative stress that contributes to the development and progression of prostate cancer (PCa), and to identify small molecules that specifically inhibit this AR-JunD interaction and prevent development/progression of PCa in preclinical models. Data from this research will identify the most efficacious drug to be further developed in preclinical toxicity testing and clinical trials for PCa that fall beyond the scope of this proposal. Significant findings during Year 3 of the research include: 1) establishment of specific inhibition of AR-JunD interaction by the lead AR-JunD inhibitor compound in prostate cancer cells via immunocytochemistry analysis, 2) establishment of the maximum tolerated dose (MTD) in an oral regimen of the lead compound in mice, and 3) preliminary evidence of efficacy of the lead compound administered at MTD oral regimen against xenograft and transgenic mouse models of prostate cancer. |             |                          |                            |                                                  |                                           |
| 15. SUBJECT TERMS<br>androgen receptor, JunD, SSAT, oxidative stress, ChIP, Gaussia luciferase reconstitution, high throughput screen, small molecule inhibitors, human prostate carcinoma cells, pharmacokinetics, prostate cancer xenograft and transgenic mouse models efficacy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |             |                          |                            |                                                  |                                           |
| 16. SECURITY CLASSIFICATION OF:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |             |                          | 17. LIMITATION OF ABSTRACT | 18. NUMBER OF PAGES                              | 19a. NAME OF RESPONSIBLE PERSON           |
| a. REPORT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | b. ABSTRACT | c. THIS PAGE             |                            |                                                  | USAMRMC                                   |
| U                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | U           | U                        | UU                         | 12                                               | 19b. TELEPHONE NUMBER (include area code) |

Table of Contents

|                                   | <u>Page</u> |
|-----------------------------------|-------------|
| Introduction.....                 | 4           |
| Body.....                         | 4           |
| Key Research Accomplishments..... | 8           |
| Reportable Outcomes.....          | 9           |
| Conclusion.....                   | 9           |
| References.....                   | 10          |
| Appendices.....                   | 10          |

## INTRODUCTION

*We hypothesize that activated androgen receptor (AR) forms a heterodimer with JunD and this AR-JunD heterodimer induces SSAT gene expression leading to polyamine oxidation and consequent production of excess reactive oxygen species (ROS) in prostate cells. Excess ROS, in turn, contribute to the development and progression of prostate cancer (PCa). The purpose of this research is to firmly establish the mechanism of the induction of SSAT by the AR-JunD complex that leads to an excess ROS production in PCa cells, identify small molecules that specifically inhibit the AR-JunD interaction downstream of androgen activation of AR in this pathway, validate the activity of the inhibitors against ROS production and growth in PCa cells, and determine the chemotherapeutic/chemopreventive efficacy of the lead inhibitors against pre-clinical mouse models of PCa. Data from this research will identify the most efficacious drug to be further developed for preclinical toxicity testing and clinical trials for PCa that fall beyond the scope of this proposal. This report summarizes the progress that has been achieved toward completing the proposed aims.*

## BODY

The following are the data collected with respect to tasks listed in our statement of work (SOW):

### Task 1. Establish the mechanistic pathway for androgen-induced SSAT expression in CaP cells (months 1-18):

- 1.1. Create mutant SSAT promoter-luciferase reporter constructs (months 1-4).*
- 1.2. Transiently transfect mutant constructs into cells and compare 1) SSAT promoter activity by luciferase reporter assay and 2) reduction in androgen-induced ROS production by DCFH dye oxidation assay (months 4-12).*
- 1.3. Perform ChIP assay to identify the AR-JunD binding sequence in most and least effective mutants (months 12-18).*

This task was completed in year 2. To recap, cell culture studies on LNCaP cells transiently transfected with SSAT promoter-luciferase reporter constructs, including three differently truncated promoter constructs and the full length promoter construct, showed enhancement of SSAT promoter activity following androgen stimulation for all but the truncated promoter with a 659 bp lead sequence. The data suggested a 3-dimensional structure of the promoter that may hide certain sections in the SSAT promoter that are important for androgen induction of SSAT. Our previously published chromatin immunoprecipitation (ChIP) data showed that a 77 bp section between 550-650 bp lead sequence is the JunD binding domain of the SSAT promoter in the presence of androgen [1]. We introduced point mutations in the AP1/JunD binding sequences within the SSAT promoter sequence and repeated the studies with these point-mutated constructs. No difference in SSAT promoter activity following androgen stimulation was observed, thus we concluded that the point mutations did not disturb JunD binding. Since the point mutations had no effect, we did not pursue the ChIP assay in cells transfected with these constructs as proposed.

### Task 2. Screen a small molecule library to identify inhibitors of AR-JunD interaction (months 1-15):

- 2.1. Optimize the GL-reconstitution screening assay conditions using the “hit” obtained from the partial screening assay performed in preliminary studies (months 1-4).*
- 2.2. Perform the optimized screen on the 14,400 compound Maybridge HitFinder library (months 4-12).*
- 2.3. Eliminate false positive “hits” by performing the positive control (SMAD3-PKB) interaction screen (months 6-15).*

This task was completed in the first year. To recap, after standardizing a more efficient high throughput screen (HTS) assay using the NCI Diversity Set library that had been used in the preliminary studies presented in the grant proposal, we completed our screen for new “hits” in a 25,000 compound Life Chemicals library, which yielded 13 small molecule drug-like compounds that specifically inhibited the AR-JunD interaction by at least 30%, and were thus advanced to Task 3.

These compounds were recently submitted for patent process. Details of these compounds will be made available under confidentiality upon request.

Task 3. Select inhibitors that act downstream to AR activation and validate compounds for activity against CaP cells (months 8-28):

*3.1 Test compounds for their ability to bind AR using an AR-LBD binding fluorescence polarization assay (months 8-26).*

*3.2 Test compounds for their ability to inhibit the translocation of AR-JunD to the cell nucleus (months 8-26).*

*3.3 Test compounds for their ability to inhibit growth of CaP cells and block androgen-induced ROS production in CaP cells (months 10-28).*

This task is essentially completed. Following our determination in Year 1 that 12 of the 13 compounds are non-antiandrogenic, we proceeded with cell culture studies in Year 2 to determine the activity of the small molecule inhibitors against androgen-induced ROS production and androgen-dependent and -independent prostate cancer cell growth. We chose the compounds to be tested in the full series of ROS and growth cell culture studies based on percent inhibition of the AR-JunD interaction by the compounds in the HTS assay: 7 of the 12 non-antiandrogenic compounds were selected for these studies based on  $\geq 50\%$  inhibition of AR-JunD in the HTS. DCF and DNA assays were used to measure the amount of ROS production and growth, respectively, in both androgen-dependent LNCaP and androgen-independent LNCaP C4-2 cell lines following our established methods [2-4]. Two compounds, GWARJD10-001 and GWARJD14-001, showed significant activity against androgen-induced ROS production and AD growth in LNCaP cells as well as LNCaP C4-2 AI growth. Both compounds had EC50s of 25  $\mu\text{M}$  or less and IC50s of 10  $\mu\text{M}$  or less, which are considered clinically relevant concentrations and thus these compounds were prioritized for further studies. Immunocytochemistry (ICC) studies to determine the ability of the top compounds GWARJD10-001 and GWARJD14-001 to inhibit the nuclear translocation of AR-JunD complex were performed in LNCaP cells treated with ROS-inducing levels of R1881 synthetic androgen and varying doses of compound. We established a quantitative ICC analysis using new, sophisticated technology - a Nuance™ fluorescence microscope (Caliper/PerkinElmer) equipped with spectral deconvolution and AUC integration software - available in the UWCCC TRIP lab. GWARJD10-001 showed significant activity against androgen-stimulated co-translocation of AR and JunD to LNCaP cell nuclei, while GWARJD14-001 was not effective at the same concentrations. However, since AR staining was less than optimal in those studies, in Year 3 we optimized the AR staining and fluorescence imaging with assistance from the UWCCC Experimental Pathology laboratory to complete ICC analysis on the top compound for publication. We used a novel ICC technique, PLA (Proximity Ligation Assay), to confirm further that the interaction of AR with JunD is inhibited by the compound GWARJD10-001. In this assay a specific antibody against each of two interacting proteins were used (eg; JunD rabbit polyclonal antibody and mouse monoclonal antibody against AR, noting antibodies have been raised in two different species). The secondary antibody for each of primary antibody does not contain any fluorescence tags. Fluorescence probes are added after the binding of the

secondary antibodies to their respective primary antibodies. Secondary antibodies contain a piece of DNA that are complementary to each other, if two secondary antibodies are close enough, the attached DNAs can form a circular DNA which then are ligated and amplified via a rolling circle mechanism. The fluorescence probes are incorporated to the amplified DNA during the rolling circle replication. With this technique we are able to quantitate the specific interaction of AR and JunD in cells. We used this DuoLink assay to show that our lead compound GWARJD10-001 blocks the androgen-induced interaction of AR-JunD in LNCaP cells (**Table 1**). The data from this study verified the increase in AR-JunD interaction following treatment with androgen: LNCaP cells treated with 2nM synthetic androgen R1881 (Vehicle Control +R) showed a 3-fold increase in AR-JunD ( $P = 3E-08$ ) compared to LNCaP cells without androgen (Vehicle Control –R). This androgen induction of AR-JunD was significantly blocked in a dose-dependent manner by GWARJD10-001, with 1uM and 5uM doses significantly decreasing AR-JunD interaction by 42% and 47% respectively compared to Vehicle Control +R cells ( $P = 0.002$  and  $0.0002$  respectively), and the 5uM dose AR-JunD level not significantly different ( $P=0.074$ ) than in LNCaP cells without androgen (Vehicle Control –R).

**Table 1. GWARJD10-001 blocks androgen-induced AR-JunD interaction in LNCaP cells.**

LNCaP cells were treated with or without 2nM androgen R1881 (R) and either 0.25% DMSO drug vehicle (Vehicle Control) or 1 or 5 uM GWARJD10-001 for 72 hours, then analyzed by DuoLink proximity ligation assay for AR and JunD interaction. Fluorescent spots resulting from AR-JunD interaction were counted and normalized to the number of cells per field using an inverted fluorescent microscope. N=12 fields counted per condition across two experiments (6 fields per experiment).

|                           | Average AR-JunD per Cell +/- S.D. |
|---------------------------|-----------------------------------|
| <b>Vehicle Control -R</b> | 0.309 +/- 0.203                   |
| <b>Vehicle Control +R</b> | 0.939 +/- 0.137                   |
| <b>1uM GWARJD10 +R</b>    | 0.549 +/- 0.343                   |
| <b>5uM GWARJD10 +R</b>    | 0.500 +/- 0.286                   |

Analysis of slides from repeat ICC studies using DuoLink is nearly complete, and we anticipate publication of our *in vitro* data within the final no-cost-extension year of this project.

**Task 4. Select the lead drug candidate for future clinical testing by comparing efficacy of 2 to 3 drug candidates in mouse models of CaP (months 6-36).**

*4.1 Screen potential drug candidates for oral bioavailability, pharmacokinetics and maximum tolerated dose in mice (months 6-28).*

*4.2 Determine efficacy of drug candidates against a CaP cell xenograft model in nude mice (months 12-32).*

*4.3 Determine efficacy of drug candidates against the TRAMP mouse model of CaP (months 15-34).*

*4.4 Complete a statistical comparison of the efficacy of drug candidates against both CaP animal models to select the lead drug for further pre-clinical testing and future clinical trial (months 34-36).*

The lead (top-ranked) compound from *in vitro* studies, GWARJD10-001, was advanced into animal studies as reported in Years 1-2. To recap, solubility of the compound was determined in our standard administration vehicle, 0.9% saline. A preliminary PK / toxicity study established that a single dose of 5 mg/kg in 6% DMSO saline by either intra venous (IV) or oral administration was well-tolerated and yielded plasma levels at 30 minutes post administration of

3.2nM for IV and .05nM for oral dosing. Thus, the compound was determined to have oral bioavailability, and is therefore an ideal candidate for clinical application.


In Year 3, additional PK and maximum tolerated dose (MTD) studies for a daily oral dosing regimen of GWARJD10-001 were undertaken. Analyses of plasma and tissue samples from these studies are ongoing. MTD studies established the regimen of 50 mg/kg oral dailyx5 every week, using a 60% DMSO in saline formulation, as MTD for use in efficacy studies. To-date, a study of efficacy against the androgen dependent LNCaP xenograft model of prostate cancer has been completed, and plans are underway to repeat. Additionally, a study of chemopreventive efficacy against the TRAMPxFVB transgenic mouse model of prostate cancer is nearly complete, and a repeat study is ongoing. A formal statistical analysis of the data is yet to be completed, but preliminary analysis of the current data from the xenograft and transgenic mouse studies, shown in **Table 2** and **Figure 1** respectively, indicate efficacy of GWARJD10-001 against these prostate cancer models. For the LNCaP xenograft efficacy study, 24 mice received a subcutaneous implant of LNCaP cells, and two weeks later were randomized to n=12 Vehicle Control (60% DMSO saline) versus n=12 GWARJD10-001 at 50 mg/kg daily oral x 5 treatment every week until sacrifice due to tumor size / decrease in body weight or body condition (Required Sacrifice), or at timed harvest at 10 weeks following initiation of treatment, which was when the majority of remaining Vehicle Control mice required sacrifice due to tumor size/body condition. The data in **Table 2** show that treatment with GWARJD10-001 (Life Chem. F1174-3266) led to a 25% decrease in the number of mice requiring sacrifice due to tumor size or decrease in body weight/condition and a nearly 2.5-fold reduction in tumor size at end of study timed harvest.

**Table 2. Efficacy of Life Chemicals compound F1174-3266 against prostate cancer xenografts.**

Athymic nude mice were xenografted with LNCaP cells, then randomized for initiation of treatment 2 weeks later. Tumor development and growth as well as body weight and condition were monitored over time to determine efficacy. *Tumor Development* : # mice that developed tumors; *Required Sacrifice* : # mice requiring sacrifice due to tumor size/ decrease in body weight or condition; *End Average Tumor Volume* : average size of tumors at timed harvest end of study.

| Xenograft Model          | Treatment              | % Tumor Development | % Required Sacrifice | End Average Tumor Volume (cu.mm) |
|--------------------------|------------------------|---------------------|----------------------|----------------------------------|
| Androgen Dependent LNCaP | Vehicle Control (n=12) | 75                  | 67                   | 434                              |
|                          | 50 mg/kg Drug (n=12)   | 67                  | 42                   | 181                              |

For the study of chemopreventive efficacy against the TRAMPxFVB model, mice were randomized to Vehicle Control (60% DMSO saline) or GWARJD10-001 at 50 mg/kg daily oral x 5 treatment every week and followed for tumor development and survival, where survival is defined by the requirement to euthanize a mouse due to tumor size. Preliminary survival data for this ongoing study are shown in **Figure 1**, indicating an early survival benefit for the mice on drug in study weeks 9-12 and prolonged survival benefit 25 weeks and beyond for 33% of the mice on drug. Imaging data from longitudinal MRI scans on subsets of the mice in each treatment group are being analyzed for analysis of tumor development over time as proposed..



**Figure 1. Efficacy of Life Chemicals compound F1174-3266 against TRAMPxFVB transgenic mouse model of prostate cancer.** TRAMPxFVB[F1] male mice of age 6 to 8 weeks were randomized to treatment with drug at 50 mg/kg (n=8) or vehicle control (n=9) oral daily x 5 every week until sacrifice due to tumor burden. Survival is defined by the requirement to sacrifice a mouse due to tumor size.

We anticipate completion of these studies within the final no-cost-extension year of this project. We may perform additional solubility / formulation studies on GVARJD10-001 to potentially improve the solubility (reduce percent DMSO in the vehicle for potentially higher doses) and determine stability in solution for long-term administration studies. Solubility / formulation analysis of GVARJD14-001 is also planned.

## KEY RESEARCH ACCOMPLISHMENTS

- Established mutant SSAT promoter-luciferase reporter constructs
- Identified relatively more important sequences in SSAT promoter for androgen induction of SSAT
- Optimized the high throughput screen for 384-well plate based assay
- Completed screening on a 25,000 compound Life Chemical (LC) library
- Identified 13 compounds as true “hits”
- Identified 12 of the 13 “hits” as non-antiandrogenic compounds
- Standardized conditions for testing the compounds for efficacy against growth and ROS production in androgen-dependent (AD) and androgen-independent (AI) human prostate carcinoma (PCa) cells in the presence or absence of androgen
- Completed cell culture studies on 7 of the non-antiandrogenic LC compounds (selected for testing based on > 50% in HTS): determined EC50s for block of ROS production, IC50s for AD and AI PCa cell growth
- Identified 2 compounds with significant activity against ROS production and PCa cell growth based on EC50s and IC50s; prioritized them for further study
- Standardized a quantitative ICC method for determining ability of compounds to reduce AR-JunD nuclear co-localization
- Performed ICC studies on top 2 compounds
- Standardized protocol for development of LC-MS analysis and testing of compounds for oral bioavailability and pharmacokinetics
- Developed a LC-MS method for the lead (rank 1) compound

- Performed a preliminary PK/toxicity analysis for the lead compound at 5 mg/kg oral versus iv (single dose); determined oral bioavailability and single dose tolerance
- Determined lead compound MTD = 50mg/kg in oral once daily x 5 per week regimen
- Initiated studies on efficacy of lead compound at MTD regimen against LNCaP xenograft and TRAMPxFVB mouse models of prostate cancer

## REPORTABLE OUTCOMES

- Kegel S, Mehraein-Ghomi F, Reuter Q, Schmidt J, Church D, Hoffmann FM, Basu H, and Wilding G. Targeting a novel pathway for prostate cancer therapy [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, Florida. Philadelphia (PA): AACR; 2011. Abstract nr 2583 (see Appendix 1)
- Schmidt J, Kegel S, Mehraein-Ghomi F, Saphner E, Reuter Q, Church D, Hoffmann FM, Basu H, and Wilding G. Inhibiting Androgen Receptor and JunD protein interaction to prevent prostate cancer progression [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31 - Apr 4; Chicago, Illinois. Philadelphia (PA): AACR; 2012. Abstract nr 2844 (see Appendix 2)
- Plasmids developed: Four different mutant SSAT promoter-luciferase reporter constructs with various degrees of truncation of the SSAT promoter connected to a luciferase reporter in a pGL4 vector; Ap1/JunD sequence point-mutated SSAT promoter-luciferase reporter constructs
- SBIR Phase I grant proposal submitted December 2010, resubmitted December 2011, funded September 2013, 1R43CA162734-01A1 "Androgen Receptor-JunD Complex Inhibitors to Prevent Prostate Cancer Progression" (Colby Pharmaceutical Company PI Hirak Basu, UW-Madison PI George Wilding)

## CONCLUSION

We have established that point mutations in the AP1/JunD consensus sequence (TGA/TCA) do not affect the binding of JunD to the SSAT promoter under androgen stimulation. However, removing bigger sequences in the SSAT promoter did significantly affect the androgen-stimulated SSAT promoter activity, and indicated a 3-dimensional structure where certain sequences important for androgen-induced SSAT activation may be hidden.

We have successfully identified drug-like small molecules that specifically inhibit the AR-JunD interaction downstream of androgen activation of the AR, and validated significant activity against androgen-induced ROS production and androgen-dependent and -independent growth in human PCa cells by two of these AR-JunD inhibitors. One of these compounds has also shown significant activity against AR-JunD co-translocation to the nucleus in the PCa cells. We have also determined that this compound is orally bioavailable. Thus, we have identified at least one small molecule AR-JunD inhibitor that shows significant promise as a potential new agent for human PCa therapy. Preliminary results of ongoing studies suggest this compound has efficacy against preclinical animal models of prostate cancer. Completion of the animal studies during this final no-cost-extension year should establish a lead compound to translate to preclinical and clinical development to treat early-stage recurrent prostate cancer patients, who have no approved therapy and represent a long unmet medical need.

## REFERENCES

1. Mehraein-Ghomi F, Basu HS, Church DR, Hoffmann FM, Wilding G. Androgen receptor requires JunD as a coactivator to switch on an oxidative stress generation pathway in prostate cancer cells. *Cancer Res.* 2010; 70(11):4560-8. PMCID: PMC2909607
2. Church DR, Lee E, Thompson TA, Basu HS, Ripple MO, Ariazi EA, Wilding G. Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells. *Prostate.* 2005;63(2):155-68.
3. Mehraein-Ghomi F, Lee E, Church DR, Thompson TA, Basu HS, Wilding G. JunD mediates androgeninduced oxidative stress in androgen dependent LNCaP human prostate cancer cells. *Prostate.* 2008;68(9):924-34.
4. Basu HS, Thompson TA, Church DR, Clower CC, Mehraein-Ghomi F, Amlong CA, Martin CT, Woster PM, Lindstrom MJ, Wilding G. A small molecule polyamine oxidase inhibitor blocks androgen-induced oxidative stress and delays prostate cancer progression in the transgenic adenocarcinoma of the mouse prostate model. *Cancer Res.* 2009; 69:7689-95. PMCID: PMC2756327.

## APPENDICES

Appendix 1: AACR 2011 abstract

Appendix 2: AACR 2012 abstract

## APPENDIX 1

### Targeting a novel pathway for prostate cancer therapy

Stacy Kegel, Farideh Mehraein-Ghomi, Quentin Reuter, Joseph Schmidt, Dawn Church, F. Michael Hoffmann, Hirak Basu, George Wilding. University of Wisconsin- Madison, Madison, WI  
*In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, Florida. Philadelphia (PA): AACR; 2011. Abstract nr 2583*

Development of an effective therapy to prevent prostate cancer (PCa) progression to castrate-resistant PCa (CRPCa) remains an unmet medical need, mainly due to a poor understanding of the mechanism of PCa progression. Reactive oxygen species (ROS) are produced in high amounts in PCa cells and play a major role in PCa development and progression. We have published that activated androgen receptor (AR)-JunD complex induces spermidine/spermine N1-acetyl transferase (SSAT), the first and regulatory enzyme in a major polyamine catabolism pathway that yields over-production of ROS specifically in the polyamine-rich PCa cells. Our recent data further suggest an intriguing mechanism of PCa progression, where AR-JunD induced SSAT expression and consequent upregulation of the transcription factor NF- $\kappa$ B may set up an autocrine feed forward loop of SSAT-ROS-NF $\kappa$ B-SSAT that can sustain ROS production and PCa cell proliferation in the absence of androgen. A focus of our current research is to identify compounds that specifically target and block steps in this novel pathway downstream to AR activation and thereby have potential to be new targeted therapeutic agents to prevent PCa progression to CRPCa in early stage progressing PCa patients with minimal side effects. In the research presented here we utilized a novel high throughput screen (HTS) assay to find compounds that prevent the initiating AR-JunD interaction step in this ROS generating pathway and tested their efficacy in PCa cells. A high throughput assay based on Gaussia Luciferase enzyme reconstitution via protein-protein interaction was used to screen the NCI diversity set library of drug like molecules to identify inhibitors of the AR-JunD interaction. Selected hits were further screened to determine their ability to bind to the AR using a published fluorescence polarization assay in order to categorize the molecules as non-antiandrogens or antiandrogens. As we intend to target the pathway downstream of AR activation, we focused on non-antiandrogens, further testing them for efficacy against androgen induced ROS generation and effect on cell growth in PCa cells in vitro by our published DCFH dye oxidation and DNA fluorescence assays. Of the 14 hits from the HTS assay of the NCI diversity set library, nine small molecules were chosen based on their drug-like chemical characteristics for further studies along with two synthesized analogs of one of the selected small molecules. We have categorized six agents as non-antiandrogens and five as having some antiandrogenic activity. Our ROS assay identified a lead non-antiandrogen compound that blocks androgen induced ROS production in PCA cells at less than 1uM concentration. This agent also significantly inhibited androgen-independent growth of PCa cells at 4uM. Data for all compounds will be presented.

## APPENDIX 2

### **Inhibiting Androgen Receptor and JunD protein interaction to prevent prostate cancer progression**

Joseph Schmidt, Stacy Kegel, Farideh Mehraein-Ghomi, Elizabeth Saphner, Quentin Reuter, Dawn Church, F. Michael Hoffmann, Hirak S. Basu, George Wilding. University of Wisconsin Carbone Cancer Center, Madison, WI

*In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31 – Apr 4; Chicago, Illinois. Philadelphia (PA): AACR; 2012. Abstract nr 2844*

Development of an effective therapy to prevent prostate cancer (PCa) progression to castrate-resistant PCa (CRPCa) remains an unmet medical need, mainly due to a poor understanding of the mechanism of PCa progression. Reactive oxygen species (ROS) are produced in high amounts in PCa cells and play a major role in PCa development and progression. Our published data show that activated androgen receptor (AR)-JunD complex induces the enzyme spermidine/spermine N1-acetyl transferase(SSAT), the first and a regulatory enzyme in a major polyamine catabolism pathway that causes over-production of ROS specifically in the polyamine-rich PCa cells. A focus of our current research is to identify compounds that specifically target and block steps in this novel pathway downstream to AR activation. Such compounds have the potential to become new targeted therapeutic agents with minimal side effects for preventing progression to CRPCa in patients with early stage progressing Pca. Here we present data on drug-like small molecule inhibitors of the AR-JunD interaction that initiates this ROS-generating pathway in PCa. A novel high throughput assay based on Gaussia Luciferase enzyme reconstitution via protein-protein interaction was used to screen NCI Diversity and Life Chemicals libraries of drug-like small molecules to identify inhibitors of the AR-JunD interaction. The 22 selected hits were categorized as antiandrogens or non-antiandrogens through the use of a published fluorescence polarization AR binding competition assay. Eighteen were identified as non-antiandrogens, acting downstream of AR activation by androgen, of which 14 were chosen for further study. In vitro studies entailed the measurement of the ability of the compounds to inhibit androgen-independent and dependent growth as well as AR-induced ROS in human PCa cells. The top three compounds exhibited significant inhibition of growth and androgen-induced ROS at concentrations of 5uM or less. Immunocytochemistry (ICC) studies were performed to determine the ability of the selected compounds to specifically inhibit the AR-JunD co-translocation to the nuclei. Based on the cell culture and ICC data, lead compounds were selected for pharmacokinetics studies to determine oral bioavailability. Detailed pharmacokinetic data of selected top compounds showing bioavailability after intravenous and oral administration will be presented.